Big drug firms could leave the UK or delay product launches unless the NHS gets another £20bn in spending a year, the pharmaceuticals trade body has said.
Lisa Anson, president of the Association of the British Pharmaceutical Industry (ABPI), set out the demand in an interview with The Times, saying health spending should rise from the current rate of 9.9 per cent of GDP to the G7 average of 11.3 per cent - around £20bn at current rates.
It amounts to "the first time, the ABPI... has laid out detailed requests for the general election campaign", says the paper.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
It adds: "Without higher health spending, companies would delay launching medicines in Britain as they were unlikely to be approved, she said. Nor would they be able to do clinical trials because they could not evaluate potential new drugs against existing best treatments if UK patients were not getting them."
Anson also warned that Britain risked becoming "a desert for healthcare innovation" and said the industry was "happy to discuss" tax rises to pay for more NHS spending.
Tory MP Jacob Rees-Mogg, however, said taxes were as high as they could go "and therefore, people who argue for more money have to say where they are going to cut. Without that, we have to view this as special pleading".
But Norman Lamb, the Liberal Democrat health spokesman, countered that there were "consequences to spending below the average" on health.
Drug companies are currently enjoying rising profits: ABPI member GlaxoSmithKline yesterday announced an increase in first-quarter profits to £2bn on revenues of £7.4bn.
However, several companies, such as Actavis and Pfizer have also been accused of overcharging the NHS for critical and life-saving drugs.
Continue reading for free
We hope you're enjoying The Week's refreshingly open-minded journalism.
Subscribed to The Week? Register your account with the same email as your subscription.
-
Labour shortages: the ‘most urgent problem’ facing the UK economy right nowSpeed Read Britain is currently in the grip of an ‘employment crisis’
-
Will the energy war hurt Europe more than Russia?
Speed Read European Commission proposes a total ban on Russian oil
-
Will Elon Musk manage to take over Twitter?
Speed Read The world’s richest man has launched a hostile takeover bid worth $43bn
-
Shoppers urged not to buy into dodgy Black Friday deals
Speed Read Consumer watchdog says better prices can be had on most of the so-called bargain offers
-
Ryanair: readying for departure from London
Speed Read Plans to delist Ryanair from the London Stock Exchange could spell ‘another blow’ to the ‘dwindling’ London market
-
Out of fashion: Asos ‘curse’ has struck again
Speed Read Share price tumbles following the departure of CEO Nick Beighton
-
Universal Music’s blockbuster listing: don’t stop me now…
Speed Read Investors are betting heavily that the ‘boom in music streaming’, which has transformed Universal’s fortunes, ‘still has a long way to go’
-
EasyJet/Wizz: battle for air supremacy
Speed Read ‘Wizz’s cheeky takeover bid will have come as a blow to the corporate ego’
